Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
She's a beast!
She's gonna run into the close...
...don't want to miss out if something comes out over the weekend.
You're excused.
I realize you're a newbie to this stock...
...so I'll just be quiet. I've been in my oposition from .0022 here in GNTA with over 600k shares and I haven't sold one and won't until I hear on FDA approval. Had I listened to oposters like you over the last few months, I would've sold out of my position long ago. I've done my DD and I know what I feel this stock should be trading at and when it gets there, that's when I'll sell.
Maybe you don't realize that if these indivuals are selling they are selling to a buyer? If they're selling well below their strike price, what's the point? These are rhetorical questions, don't feel the need to respond. You can't teach me anything.
Then a 9 dollar sell brings it back to 95 LOL
MM's aren't dropping thier ask price...
...for the first time in ages.
Gonna get exciting guys...
...lets see if Arm has any idea what he's talking about.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35750751
Well with 3 anticancer drugs in late stage trials...
...anyone with half a brain cell knows that at under ONE FRIGGIN PENNY, this is absurd.
Sale of the friggin' century.
Somebody likes it!
Don't get caught with your pants down...
...this weekend.
We're about to move back over a penny, just be patient and look at the chart over a 3 month period.
It's important to see the forest through the trees.
I've seen folks...
...freak out several times on this stock over the past 3 months, yet those with cooler heads have always prevailed. It's kind of humorous.
It's operfect overall bullish behavior. It makes runs up, it pulls back 1/3rd of the previous run, it accumulates, it makes it's next run up. It's a beautiful, beautiful chart.
Higher highs and lower lows. Just RELAX and enjoy it. You can't be in a stock that goes up every single day for months and months.
Genta is a great stock to be in with a hell of a lot on the line for 2009. At a penny, this is an absolute STEAL.
GUYS...
...look at the friggin charts. We're following the same trends we've followed for months now. It makes runs us, it retraces 1/3rd of the previous run, then it makes it's next run up.
Relax. The next leg up is coming soon to a chart near you.
Look at the chart, sir...
....you'll quickly realize this trend has been going on for quite some time. Just relax and enjoy it. You're sitting on a beast right now if you're in GNTA.
http://stockcharts.com/h-sc/ui?s=gnta
That is a fairy tale...
...there are no signals. Trust me, that's nonsense.
I read on another board that we are under attack by martians and they're vaporizing towns starting with Salt Lake City, Utah and working backwards alphabetically.
It's important for folks to realize...
...that Genta has more than one bullet in the gun. It's got genasense in CLL that's up for FDA ruling within 30 days, sure that's one. But it also has the Agenda trial that's showing some overwhelming results of genasense in melanoma. That's 2. Then it has the equalizer, Tesetaxel, loaded in the canon.
The future of this company doesn't ride on just the approval or denial of Genasense in CLL.
That's great news...
...there is no other stock on any board anywhere that has a late stage pipeline like Genta at this absurdly low price.
I expect to see gains similar to yesterday up until FDA approval/denial. People don't want to miss an opportunity like this one, so their holding their shares while others are also wanting to get on board.
What's important for everyone to realize (including you, griff) is that there is more than one drug and one drug application in Genta's pipeline.
I'm particularly excited about Genasense in Melanoma which is still in accrual mode, late Stage III showing incredible results.
You also have to love tesetaxel...that has the potential to be a multi, multi, billion dollar drug. I can certainly see a big pharma wanting to get in on a piece of that action.
Well that's fine, griff. The fact of the matter is that you were beating this stock down a few months ago saying that it would never perform and it did. Now you're here again saying that it'll never perform yet again...your credibility on performance predictions is in question at this point. LOL
griff mistake #1 "I wouldn't buy then"
griff mistake #2 "I'm not buying now"
124 x 126
It may not matter right this minute, but it certainly gives you an idea on where the stock will open.
Look, we know you're jaded on this stock for some reason. You're one of the original bash brothers with Durango who said this stock was dead and would never see above .004.
You were wrong then and you're wrong now. Your track record of being incorrect is growing by the week. LOL
Because the bid is higher than the close?
Thank you, sir.
I think there are a lot of people who are holding this stock now instead of flipping it like they have over the past week or 2. There's a lot on the line for this company over the next quarter. Uopside potential is out of this world.
Thanks for the breakdown.
-Holding
MrBigz....
...I was wondering if you might have time to revisit the GNTA chart for me. I know that you must be busy with all your picks and requests...but if you had some downtime, man I know I'd really appreciate it a lot. Thanks, if so, and if not that's cool too!
-Holding
Hang on guys, something is going on
It may be hard to catch this one this morning.
...gotta hit the ask price. There were lots of people on that call Friday, the vast majority which don't participate in these silly messageboards.
Diluted 950 million...
...when the thought was that we were diluted with 6 billion.
You tell me how this stock isn't going to run with 1/6th the o/s as originally thought?
It's not hype. The o/s is 950 million...and people were investing with the thought of 6 billion on the street. That's significant.
Big pharma's are interested in all 3 Genta anti-cancer products...man, this is one you just can't afford not to be in.
Did you sell your shares on Friday?
The PR put out by Genta was better than anyone could've hoped for. Everyone knows this is a company in research and development mode. Not many bring in dollars, so saving dollars is making dollars in this business.
Further, people were operating and investing with the thought that there could very well be as many as 6 billion shares on the street. Yet Genta announced that there were only 950 million.
Genta stated that there are bigger pharmas that are interested in all 3 anticancer drugs in Genta's pipeline. With the viral effect of the aquisition dominos we've been seeing lately, a comany like Genta is a prime candidate.
There's a lot of things to be excited about if you're a Genta shareholder right now. Those who have sold are going to discredit the company for one of 2 reasons.
1) Self-validation (Hey, look it's dropping, I did the right thing)
2) Attempt to drive the pps down for a lower entry.
Genta has its feet firmly on the ground. All company information is out in the open for all to see and it's much better than any investor who has done their DD could have hoped for.
Genta is going to run nicely, and continue to run the way it has since mid-December 2008. There will be people who bash and lose, and their will be people who buy and hold who win, look at the charts trend.
http://stockcharts.com/c-sc/sc?s=gnta&p=D&yr=0&mn=9&dy=0&i=p93834726544&r=3658
The stock is moving up and the next big leg starts at 9:30AM EST tomorrow morning.
Oh it is a Euro cent!
I need to stick to the good ole US of A denominations.
Time to make some Green baby.
Who wishes the market was open tomorrow? :)
No one thinks that bro...
...it was clearly stated, twice, that there are approximately 950 million shares outstanding. That's less than one billion. Educated investors factored in a 6 Billion o/s as a possibility with their investment. I was going to be excited with anything under 2 billion, to be honest.
It was great news.
He's right.
The majority of investors who have done DD on the company factored in a 6 Billion o/s into their investment. Cutting that by 1/6th to less than 1 billion is going to send this stock running Tuesday morning and for the next month.
Genta continues to climb from it's December fall very methodically. Look at the charts.
Tuesday marks the next huge volume spike and the pps is going to really move quickly.
Screenshot...
Nice ad here!
My wife is a participant on the Charlottemommies.com forum here in Charlotte, NC. This is a site that has literally thousands of women participants. Check out the top of the page! Nice!
Eventually they're going to have to...
...approve this life saving drug. The evidence is overwhelming and the pressure is really building from all angles.
Great read...
http://dogbrothers.com/phpBB2/index.php?
May 4, 2007; Page A15
The Food and Drug Administration recently argued in the D.C. Court of Appeals that it has the power to ban meat and vegetables without violating anyone's fundamental rights. The agency chose this bizarre position in an attempt to counter arguments made by patients and their advocates in Abigail Alliance v. von Eschenbach. This groundbreaking case challenges the agency's refusal to grant access to investigational drugs, even as a last resort for terminally ill patients.
Last year, a three-judge panel decided that the FDA is violating the due- process rights of terminally ill patients by denying them access to promising investigational drugs. In response the FDA moved for a rehearing by the full court, hoping to prevent a lower court-supervised examination of whether its draconian policies actually serve a narrowly tailored compelling governmental interest. In layman's terms, this means the FDA would have to show its policies toward terminal patients are so critical to the well-being of society that they supersede (in broad and highly imperfect fashion) the fundamental right of an individual to pursue life free of undue government interference. The FDA knows their policies will not survive this test, and doesn't want the question asked.
Consider the FDA's handling of Genasense, a new drug for melanoma and chronic lymphocytic leukemia (CLL), two often terminal forms of cancer. The drug is being developed by Genta, a small, innovative company with only one approved drug and limited financial resources. Despite compelling evidence that Genasense is making progress in fighting both diseases, the FDA appears determined to kill the drug.
In the case of the melanoma application, instead of reviewing the clinical-trial data in accordance with usual methods (which showed positive results), the FDA chose a nonstandard statistical approach aimed at discrediting the results. The agency used this analysis in its briefing to its advisory committee, claiming that the drug might not be effective. The committee then relied on that information to vote against approval.
Now, Genta has found a serious mathematical error in the FDA's analysis, rendering its results meaningless. Genta is filing a complaint under the Federal Data Quality Act to correct the record. But in the meantime, the drug remains unapproved and melanoma patients continue to wait.
Genasense was also shown in a well-run, randomized clinical trial (the FDA's gold standard) to cause a complete disappearance of disease in 17% of patients with advanced CLL when combined with two older drugs. Just 7% of patients in a control group who received only the older drugs experienced similar benefit. The responders to Genasense have seen their relief last an average of 36 months, while those using other drugs saw their cancer return, on average, in 22 months.
Following these results, the Director of the FDA's cancer division, Dr. Richard Pazdur, again convened a public meeting of his advisory committee. After an agency presentation designed to elicit a negative outcome, the panel voted 7 to 3 against approval, triggering an immediate reaction of surprise and dismay among many CLL experts.
But the committee vote is less surprising if one knows that the FDA appointed several voting consultants to the committee (none of them CLL experts), and recused from the meeting the only sitting member of the committee who is an expert in CLL. Perhaps even more troubling, two of the voting committee members worked behind the scenes as undisclosed consultants for the FDA on Genasense, then without disclosure voted in the open meeting.
A shocked Genta quickly requested a meeting with the FDA to seek clarity on the agency's position, and to present additional information from patient follow-up. On the referral of an eminent leukemia expert, Genta asked if we would attend the meeting as witnesses in our capacity as patient advocates. No compensation was offered, requested or received.
Most of the meeting was consumed by getting the FDA to admit the obvious: The long-lasting, complete disappearance of CLL and its symptoms constituted "clinical benefit." Making these arguments were two cancer-medicine professors at M.D. Anderson Cancer Center, the recused ODAC member and an immediate past president of the American Society of Hematology -- all experts in CLL. None were employees of Genta and collectively represented a far more qualified advisory committee than the one that the FDA had convened.
The FDA's inane answer to the CLL experts was that the long-lasting disappearance of disease in patients taking Genasense was a "theoretical construct" and not grounds for approval.
The experts explained to the FDA that complete responses in advanced CLL patients are the medical equivalent of the Holy Grail. The FDA finally agreed, but was unimpressed with emerging data showing responders to Genasense living longer than responders in the control group.
The experts were unanimous in advising that Genasense should be approved, but the FDA was unmoved. The agency's Dr. Pazdur suggested that Genta could make the drug available as an unapproved treatment through an expanded access program -- this from a regulator fond of stating that the best way to get a drug to patients in need is through approval! In this case the agency was saying to Genta: We are not going to approve your drug, but any patient who needs it can have it so long as you give it away.
Genta responded that nonapproval would be a denial of patient access to Genasense because they could not afford to give it away in an expanded access program. Twice, Dr. Pazdur referred to that logic as a "business decision."
Less than 48 hours later, the FDA rejected Genasense. Within days Genta made a "business decision," laying off a third of its staff in a cost cutting move aimed at keeping the doors open long enough to appeal the FDA's decision. The appeal was filed in early April. Genta's announcement of the filing included a statement from one of the expert physicians: "It is puzzling that they would deny approval to a drug that met its primary and key secondary endpoint, especially since these findings were observed in the only randomized controlled trial that has ever been conducted in patients with relapsed CLL."
The FDA's handling of Genasense lays bare the all too common, aggressive incompetence of the FDA's cancer-drug division and should lead to an immediate examination of its policies and leadership, followed by swift corrective action.
As for the FDA's belief that their power to control us and even deny us the pursuit of life itself is unlimited under the Constitution, we can only hope the appeals court disagrees. An agency that blocks progress against deadly diseases -- while arguing that its power to do so is above challenge -- is in dire need of a court supervised review.
Mr. Walker is co-founder and chief adviser for the Abigail Alliance for Better Access to Developmental Drugs . He receives no compensation for his work as an advocate, nor has he ever received compensation from any private or public-sector entity involved in drug development, approval or marketing.
I want people to go look at...
...the charts since December. Look at the pps movement and the volumes. Anyone see a trend? It doesn't take a genius to see what's on the way, especially after that conference call. Talking explosive potential.
It's hilarious...
...shorts are completely f@#%#d and they're STILL trying to hold on to something that simply isn't there any more after todays meeting.
Sorry boys, you're about to get your brains squeezed out. Gotta go ahead and suck it up!
HELL YEAH TIME TO ROLL!
What happened? :)